インサイダー取引

EDGAR

Scribe Therapeutics, Inc.

取締役、役員、10%超の株主がSECのForm 3、4、5で報告した取引を、各提出書類のXMLから読み取っています。コードとその文言はSEC自身のものです。

Form 4は取引から2営業日以内に提出する必要があるため、直近の取引はまだ提出されていない場合があります。

期間:2025年11月18日以降の日付の取引。

市場での購入(コードP)
9件の取引、4,730,237株
株数 × 1株あたり価格の合計:71,344,746.25
市場での売却(コードS)
0件の取引、—株

合計は掲載した提出済み取引を足したもので、報告された内容の集計であり、方向性を示すものではありません。

35件中1–35件を表示

SECのForm 3、4、5で提出されたインサイダー取引(新しい順)
日付報告者コード取得または処分株数1株あたり価格(提出どおり)価値(算出)取引後の保有株数直接または間接ルール10b5-1のチェック欄注記出典
2026年7月28日 2026年7月28日に提出Aghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
P

Open market or private purchase of non-derivative or derivative security

Common Stock, par value $0.0001 per share
取得(A)7,90518.25
144,266.25

算出:株数 × 1株あたり価格。正確な値 144266.25。

3,088,888間接(I) See footnotesいいえ
F2, F3, F6, F4, F5
  • F2 The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.
  • F3 Of the 3,088,888 shares reported in Column 5, 2,598,973 shares are held by Avoro Life Sciences and 489,915 shares are held by Avoro Ventures Fund.
  • F6 The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.
  • F4 The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (Avoro Capital Advisors) serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (Avoro Ventures) serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
  • F5 Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
提出書類を開く 0000902664-26-003270 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月27日 2026年7月29日に提出AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Common Stock
取得(A)2,051,742——2,051,742間接(I) By AH Bio Fund II, L.P.いいえ
F1, F2
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F2 The reported securities are held by AH Bio Fund II, L.P. (AH Bio Fund II), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. (AH EP Bio II) is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
提出書類を開く 0001231919-26-000813 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月27日 2026年7月29日に提出AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

Common Stock
取得(A)697,650——697,650間接(I) By AH Bio Fund III, L.P.いいえ
F1, F3, F4
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F3 The reported securities are held by AH Bio Fund III, L.P. (AH Bio Fund III), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. (AH EP Bio III) is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.
  • F4 (Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
提出書類を開く 0001231919-26-000813 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月27日 2026年7月29日に提出AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
取得(A)333,33315
4,999,995

算出:株数 × 1株あたり価格。正確な値 4999995。

2,385,075間接(I) By AH Bio Fund II, L.P.いいえ
F2
  • F2 The reported securities are held by AH Bio Fund II, L.P. (AH Bio Fund II), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. (AH EP Bio II) is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
提出書類を開く 0001231919-26-000813 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月27日 2026年7月29日に提出AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

デリバティブ証券: Series A Preferred Stock — 原資産 Common Stock (2,051,742)
処分(D)12,150,0030—0間接(I) By AH Bio Fund II, L.P.いいえ
F1, F2
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F2 The reported securities are held by AH Bio Fund II, L.P. (AH Bio Fund II), for itself and as nominee for AH Bio Fund II-B, L.P. AH Equity Partners Bio II, L.L.C. (AH EP Bio II) is the general partner of AH Bio Fund II and has sole voting and dispositive power with regard to the securities held by AH Bio Fund II for itself and as nominee. The managing members of AH EP Bio II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund II for itself and as nominee. Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
提出書類を開く 0001231919-26-000813 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月27日 2026年7月29日に提出AH Bio Fund II, L.P. 10% ownerAH Equity Partners Bio II, L.L.C. 10% ownerAH Bio Fund III, L.P. 10% ownerAH Equity Partners Bio III, L.L.C. 10% ownerAndreessen Marc L 10% ownerHOROWITZ BENJAMIN A 10% owner
C

Conversion of derivative security

デリバティブ証券: Series B Preferred Stock — 原資産 Common Stock (697,650)
処分(D)4,131,3440—0間接(I) By AH Bio Fund III, L.P.いいえ
F1, F3, F4
  • F1 Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
  • F3 The reported securities are held by AH Bio Fund III, L.P. (AH Bio Fund III), for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP. AH Equity Partners Bio III, L.L.C. (AH EP Bio III) is the general partner of AH Bio Fund III and has sole voting and dispositive power with regard to the securities held by AH Bio Fund III for itself and as nominee. The managing members of AH EP Bio III are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund III for itself and as nominee.
  • F4 (Continued from Footnote 3) Each of the Reporting Persons disclaims the existence of a group and disclaims beneficial ownership of the securities held by AH Bio Fund III for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.
提出書類を開く 0001231919-26-000813 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月27日 2026年7月29日に提出ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
C

Conversion of derivative security

Common Stock
取得(A)348,825——348,825間接(I) See footnotesいいえ
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
提出書類を開く 0000947871-26-000733 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月27日 2026年7月29日に提出ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
取得(A)1,000,00015
15,000,000

算出:株数 × 1株あたり価格。正確な値 15000000。

1,348,825間接(I) See footnotesいいえ
F2, F3, F4
  • F2 Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
提出書類を開く 0000947871-26-000733 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月27日 2026年7月29日に提出ORBIMED ADVISORS LLC DirectorOrbiMed Capital GP VIII LLC Director
C

Conversion of derivative security

デリバティブ証券: Series B Preferred Stock — 原資産 Common Stock (348,825)
処分(D)2,065,6720—0間接(I) See footnotesいいえ
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
提出書類を開く 0000947871-26-000733 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月27日 2026年7月29日に提出GORDON CARL L Director
C

Conversion of derivative security

Common Stock
取得(A)348,825——348,825間接(I) See footnotesいいえ
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
提出書類を開く 0000947871-26-000734 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月27日 2026年7月29日に提出GORDON CARL L Director
P

Open market or private purchase of non-derivative or derivative security

Common Stock
取得(A)1,000,00015
15,000,000

算出:株数 × 1株あたり価格。正確な値 15000000。

1,348,825間接(I) See footnotesいいえ
F2, F3, F4
  • F2 Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
提出書類を開く 0000947871-26-000734 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月27日 2026年7月29日に提出GORDON CARL L Director
C

Conversion of derivative security

デリバティブ証券: Series B Preferred Stock — 原資産 Common Stock (348,825)
処分(D)2,065,6720—0間接(I) See footnotesいいえ
F1, F3, F4
  • F1 Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date.
  • F3 The shares are held directly by OrbiMed Private Investments VIII, LP (OPI VIII). OrbiMed Capital GP VIII LLC (GP VIII) is the general partner of OPI VIII. OrbiMed Advisors LLC (OrbiMed Advisors) is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
  • F4 Each of the Reporting Person, OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the Exchange Act), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
提出書類を開く 0000947871-26-000734 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月27日 2026年7月29日に提出Doudna Jennifer A 10% owner
C

Conversion of derivative security

Common Stock
取得(A)12,511——603,547直接(D) いいえ
F1
  • F1 Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.
提出書類を開く 0001739090-26-000010 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月27日 2026年7月29日に提出Doudna Jennifer A 10% owner
C

Conversion of derivative security

デリバティブ証券: Series A-1 Preferred Stock — 原資産 Common Stock (12,511)
処分(D)74,088——0直接(D) いいえ
F1
  • F1 Each share of Series A-1 Preferred Stock is convertible into Common Stock on a one-for 0.1689 basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock has no expiration date.
提出書類を開く 0001739090-26-000010 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月24日 2026年7月28日に提出Aghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
P

Open market or private purchase of non-derivative or derivative security

Common Stock, par value $0.0001 per share
取得(A)2,333,33315.00
34,999,995

算出:株数 × 1株あたり価格。正確な値 34999995.00。

3,030,983間接(I) See footnotesいいえ
F1, F6, F4, F5
  • F1 The shares reported on this line were purchased from underwriters in the Issuer's initial public offering (the IPO) at the initial public offering price of $15.00 per share. Of such shares, 2,066,666 shares were purchased on behalf of Avoro Life Sciences Fund LLC (Avoro Life Sciences) and 266,667 shares were purchased on behalf of Avoro Ventures Fund L.P. (Avoro Ventures Fund and, together with Avoro Life Sciences, the Funds).
  • F6 The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.
  • F4 The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (Avoro Capital Advisors) serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (Avoro Ventures) serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
  • F5 Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
提出書類を開く 0000902664-26-003270 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月24日 2026年7月28日に提出Aghazadeh Behzad Director · 10% owner · Other: See RemarksAvoro Capital Advisors LLC Director · 10% owner · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
P

Open market or private purchase of non-derivative or derivative security

Common Stock, par value $0.0001 per share
取得(A)50,00022.31
1,115,500

算出:株数 × 1株あたり価格。正確な値 1115500.00。

3,080,983間接(I) See footnotesいいえ
F2, F6, F4, F5
  • F2 The shares reported on these lines were purchased on behalf of Avoro Life Sciences in open market transactions on the dates provided in Column 2.
  • F6 The amount reported in Column 5 includes 697,650 shares of Common Stock issuable upon conversion of shares of the Issuer's Series B Preferred Stock held by the Funds, which shares were reported on an as-converted basis in the Reporting Persons' Form 3 filed on July 23, 2026. Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-0.1689 basis at the option of the holder and converted automatically into Common Stock, without the payment of any consideration, upon the closing of the IPO on July 27, 2026. No transaction is reported in Table I or Table II with respect to the conversion.
  • F4 The securities reported herein are held directly by Avoro Life Sciences and Avoro Ventures Fund. Avoro Capital Advisors LLC (Avoro Capital Advisors) serves as investment adviser to Avoro Life Sciences, and Avoro Ventures LLC (Avoro Ventures) serves as investment adviser to Avoro Ventures Fund. Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures. By virtue of these relationships, each of the Reporting Persons may be deemed to beneficially own the securities held by the Funds.
  • F5 Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. The shares reported herein are held on behalf of the Funds and other managed accounts, within the meaning of Rule 16a-1(a)(2).
提出書類を開く 0000902664-26-003270 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月28日に提出Staahl Brett 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (19,385) — 行使価格 15
取得(A)19,3850—19,385直接(D) いいえ
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
提出書類を開く 0002147277-26-000003 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月28日に提出Staahl Brett 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Performance-based Stock Option (Right to Buy) — 原資産 Common Stock (19,385) — 行使価格 15
取得(A)19,3850—19,385直接(D) いいえ
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
提出書類を開く 0002147277-26-000003 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Lucas Svetlana Officer: Chief Business Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
取得(A)3,00015
45,000

算出:株数 × 1株あたり価格。正確な値 45000。

3,000間接(I) By Spouseいいえ— 提出書類を開く 0001781292-26-000007 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Lucas Svetlana Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (109,426) — 行使価格 15
取得(A)109,4260—109,426直接(D) いいえ
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
提出書類を開く 0001781292-26-000007 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Lucas Svetlana Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Performance-based Stock Option (Right to Buy) — 原資産 Common Stock (109,426) — 行使価格 15
取得(A)109,4260—109,426直接(D) いいえ
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
提出書類を開く 0001781292-26-000007 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Oakes Benjamin L. Director · Officer: President, CEO · Other: Chairman of the Board
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (264,784) — 行使価格 15
取得(A)264,7840—264,784直接(D) いいえ
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
提出書類を開く 0002127814-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Oakes Benjamin L. Director · Officer: President, CEO · Other: Chairman of the Board
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Performance-based Stock Option (Right to Buy) — 原資産 Common Stock (429,599) — 行使価格 15
取得(A)429,5990—429,599直接(D) いいえ
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
提出書類を開く 0002127814-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Watson James Dean Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (14,725) — 行使価格 15
取得(A)14,7250—14,725直接(D) いいえ
F1
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
提出書類を開く 0002130384-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Aghazadeh Behzad Director · Other: See RemarksAvoro Capital Advisors LLC Director · Other: See RemarksAvoro Ventures LLC Director · Other: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (14,725) — 行使価格 15
取得(A)14,7250—14,725直接(D) いいえ
F1, F2, F3
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to Behzad Aghazadeh's (Dr. Aghazadeh) provision of service to the Issuer on each vesting date.
  • F2 This Form 4 is filed by Dr. Aghazadeh, Avoro Capital Advisors LLC, a Delaware limited liability company (Avoro Capital Advisors), and Avoro Ventures LLC, a Delaware limited liability company (Avoro Ventures, together with Dr. Aghazadeh and Avoro Capital Advisors, the Reporting Persons). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.
  • F3 The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
提出書類を開く 0000902664-26-003254 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Bleharski Joshua Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (14,725) — 行使価格 15
取得(A)14,7250—14,725直接(D) いいえ
F1
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
提出書類を開く 0002075052-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出GORDON CARL L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (14,725) — 行使価格 15
取得(A)14,7250—14,725直接(D) いいえ
F1
  • F1 The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
提出書類を開く 0001282930-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Parrot David Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
取得(A)1,33315
19,995

算出:株数 × 1株あたり価格。正確な値 19995。

1,333間接(I) By Spouseいいえ— 提出書類を開く 0002127908-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Parrot David Officer: Chief Financial Officer
P

Open market or private purchase of non-derivative or derivative security

Common Stock
取得(A)1,33315
19,995

算出:株数 × 1株あたり価格。正確な値 19995。

1,333間接(I) By Childいいえ— 提出書類を開く 0002127908-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Parrot David Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (109,426) — 行使価格 15
取得(A)109,4260—109,426直接(D) いいえ
F3
  • F3 The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
提出書類を開く 0002127908-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年7月23日 2026年7月27日に提出Parrot David Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Performance-based Stock Option (Right to Buy) — 原資産 Common Stock (109,426) — 行使価格 15
取得(A)109,4260—109,426直接(D) いいえ
F4
  • F4 The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
提出書類を開く 0002127908-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年3月13日 2026年7月28日に提出Staahl Brett 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (4,755) — 行使価格 19.13
取得(A)4,7550—4,755直接(D) いいえ
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
提出書類を開く 0002147277-26-000003 提出書類のXMLから読み取り この行に異議を申し立てる
2026年3月13日 2026年7月27日に提出Lucas Svetlana Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (9,547) — 行使価格 19.13
取得(A)9,5470—9,547直接(D) いいえ
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
提出書類を開く 0001781292-26-000007 提出書類のXMLから読み取り この行に異議を申し立てる
2026年3月13日 2026年7月27日に提出Oakes Benjamin L. Director · Officer: President, CEO · Other: Chairman of the Board
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (12,969) — 行使価格 19.13
取得(A)12,9690—12,969直接(D) いいえ
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
提出書類を開く 0002127814-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる
2026年3月13日 2026年7月27日に提出Parrot David Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

デリバティブ証券: Stock Option (Right to Buy) — 原資産 Common Stock (8,909) — 行使価格 19.13
取得(A)8,9090—8,909直接(D) いいえ
F1, F2
  • F1 The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
  • F2 The option is fully vested.
提出書類を開く 0002127908-26-000004 提出書類のXMLから読み取り この行に異議を申し立てる

機関投資家の保有(Form 13F)

2026-09-30終了の四半期:提出書類8,793件を読み込み、最新の提出日は2026年11月17日です。 2026-06-30終了の前四半期:提出書類9,164件を読み込みました。

62件中1–50件を表示

機関投資家の保有(大きい順、提出どおり)
運用者株数または元本提出どおりの価値前四半期との差出典
a16z Capital Management, L.L.C. 3,082,725 SH56,737,554 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001540358-26-000014 2026年11月16日に提出 この行に異議を申し立てる
Avoro Capital Advisors LLC 2,598,973 SH47,834,098 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001104659-26-127608 2026年11月16日に提出 この行に異議を申し立てる
RA CAPITAL MANAGEMENT, L.P. 1,802,178 SH33,169,086 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001104659-26-128411 2026年11月16日に提出 この行に異議を申し立てる
ORBIMED ADVISORS LLC 1,348,825 SH24,825,124 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001172661-26-005349 2026年11月16日に提出 この行に異議を申し立てる
PERCEPTIVE ADVISORS LLC 920,341 SH16,938,876 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001012975-26-001063 2026年11月16日に提出 この行に異議を申し立てる
ARK Investment Management LLC 786,921 SH14,483,278 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001104659-26-126785 2026年11月13日に提出 この行に異議を申し立てる
BAKER BROS. ADVISORS LP 688,691 SH12,675,358 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001104659-26-128308 2026年11月16日に提出 この行に異議を申し立てる
PRICE T ROWE ASSOCIATES INC /MD/ 一部は別の運用者の名義で報告684,706 SH12,603 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000080255-26-000736 2026年11月16日に提出 この行に異議を申し立てる
BlackRock, Inc. 一部は別の運用者の名義で報告679,786 SH12,511,461 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0002012383-26-003985 2026年11月13日に提出 この行に異議を申し立てる
Sanofi 500,000 SH9,202,500 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001193125-26-448717 2026年11月5日に提出 この行に異議を申し立てる
VANGUARD CAPITAL MANAGEMENT LLC 407,630 SH7,502,430 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0002100119-26-001711 2026年11月13日に提出 この行に異議を申し立てる
FRANKLIN TEMPLETON INC 一部は別の運用者の名義で報告380,019 SH6,376,719 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000038777-26-000291 2026年11月12日に提出 この行に異議を申し立てる
ADAGE CAPITAL PARTNERS GP, L.L.C. 380,000 SH6,993,900 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001172661-26-005200 2026年11月16日に提出 この行に異議を申し立てる
FARALLON CAPITAL MANAGEMENT, L.L.C. 380,000 SH6,993,900 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000908834-26-000540 2026年11月16日に提出 この行に異議を申し立てる
GEODE CAPITAL MANAGEMENT, LLC 一部は別の運用者の名義で報告245,412 SH4,518,022 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001214717-26-000012 2026年11月6日に提出 この行に異議を申し立てる
STATE STREET CORP 一部は別の運用者の名義で報告171,147 SH3,149,961 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000093751-26-000747 2026年11月12日に提出 この行に異議を申し立てる
Alyeska Investment Group, L.P. 150,000 SH2,760,750 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001172661-26-005329 2026年11月16日に提出 この行に異議を申し立てる
Menlo Ventures Management, L.P. 97,690 SH1,797,984 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001911541-26-000014 2026年11月6日に提出 この行に異議を申し立てる
TD ASSET MANAGEMENT INC 83,342 SH1,919,366 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001193125-26-460060 2026年11月13日に提出 この行に異議を申し立てる
Amova Asset Management Americas, Inc. 一部は別の運用者の名義で報告74,910 SH1,378,344 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001140361-26-043552 2026年11月13日に提出 この行に異議を申し立てる
Sumitomo Mitsui Trust Group, Inc. 一部は別の運用者の名義で報告74,910 SH1,378,719 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001214659-26-013361 2026年10月29日に提出 この行に異議を申し立てる
NORTHERN TRUST CORP 一部は別の運用者の名義で報告74,721 SH1,375,240 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000073124-26-000067 2026年11月16日に提出 この行に異議を申し立てる
UBS Group AG 一部は別の運用者の名義で報告71,067 SH1,307,988 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001610520-26-000121 2026年11月10日に提出 この行に異議を申し立てる
VANGUARD PORTFOLIO MANAGEMENT LLC 67,039 SH1,233,853 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0002100121-26-001150 2026年11月13日に提出 この行に異議を申し立てる
VANGUARD FIDUCIARY TRUST CO 64,267 SH1,182,834 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000933478-26-000017 2026年11月13日に提出 この行に異議を申し立てる
Nuveen, LLC 一部は別の運用者の名義で報告41,470 SH763,255 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000930413-26-003284 2026年11月10日に提出 この行に異議を申し立てる
IQ EQ FUND MANAGEMENT (IRELAND) Ltd 40,876 SH0 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001213900-26-119414 2026年11月13日に提出 この行に異議を申し立てる
Longaeva Partners L.P. 一部は別の運用者の名義で報告34,034 SH626,396 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001193125-26-463222 2026年11月16日に提出 この行に異議を申し立てる
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 31,644 SH582,408 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000884546-26-000417 2026年11月16日に提出 この行に異議を申し立てる
BANK OF AMERICA CORP /DE/ 一部は別の運用者の名義で報告27,589 SH507,776 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000070858-26-000589 2026年11月16日に提出 この行に異議を申し立てる
Point72 Asset Management, L.P. 22,771 SH419,100 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000919574-26-008126 2026年11月16日に提出 この行に異議を申し立てる
WELLS FARGO COMPANY/MN 一部は別の運用者の名義で報告22,500 SH414,112 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000072971-26-000342 2026年11月16日に提出 この行に異議を申し立てる
GOLDMAN SACHS GROUP INC 一部は別の運用者の名義で報告21,635 SH398,192 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000886982-26-000647 2026年11月16日に提出 この行に異議を申し立てる
Bank of New York Mellon Corp 一部は別の運用者の名義で報告20,396 SH375,389 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001390777-26-000121 2026年11月5日に提出 この行に異議を申し立てる
Focus Partners Wealth 20,025 SH368,560 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001542153-26-000021 2026年11月12日に提出 この行に異議を申し立てる
SUSQUEHANNA INTERNATIONAL GROUP, LLP 一部は別の運用者の名義で報告13,641 SH251,063 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001446194-26-000009 2026年11月16日に提出 この行に異議を申し立てる
SEVEN GRAND MANAGERS, LLC 10,000 SH184,050 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001420506-26-002775 2026年11月16日に提出 この行に異議を申し立てる
RHUMBLINE ADVISERS 8,897 SH163,742 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001115418-26-000015 2026年11月10日に提出 この行に異議を申し立てる
MORGAN STANLEY 一部は別の運用者の名義で報告8,536 SH157,106 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000895421-26-000309 2026年11月13日に提出 この行に異議を申し立てる
DEUTSCHE BANK AG\ 一部は別の運用者の名義で報告8,269 SH152,233 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000948046-26-000083 2026年11月6日に提出 この行に異議を申し立てる
JPMORGAN CHASE CO 一部は別の運用者の名義で報告6,028 SH138,825 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000019617-26-000404 2026年11月12日に提出 この行に異議を申し立てる
MetLife Investment Management, LLC 一部は別の運用者の名義で報告5,814 SH107,007 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001628280-26-073956 2026年11月16日に提出 この行に異議を申し立てる
CITIGROUP INC 一部は別の運用者の名義で報告4,742 SH87,277 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000831001-26-000052 2026年11月4日に提出 この行に異議を申し立てる
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 一部は別の運用者の名義で報告4,636 SH85,326 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000905148-26-004850 2026年11月16日に提出 この行に異議を申し立てる
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC 4,195 SH77,209 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001398344-26-020056 2026年11月13日に提出 この行に異議を申し立てる
Vanguard Global Advisers, LLC 3,592 SH66,111 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001811242-26-000017 2026年11月13日に提出 この行に異議を申し立てる
TEMA ETFS LLC 3,046 SH56,062 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001829126-26-011223 2026年10月16日に提出 この行に異議を申し立てる
STRS OHIO 2,600 SH47,853 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0000820478-26-000018 2026年10月30日に提出 この行に異議を申し立てる
BNP PARIBAS FINANCIAL MARKETS 一部は別の運用者の名義で報告2,400 SH44,172 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0001166588-26-000012 2026年11月12日に提出 この行に異議を申し立てる
Police Firemen's Retirement System of New Jersey 一部は別の運用者の名義で報告2,289 SH42,129 ドル前四半期の読み込み済み提出書類にはなし 提出書類を開く 0002040686-26-000007 2026年11月9日に提出 この行に異議を申し立てる
  • Form 13Fは第13(f)条対象証券のロング・ポジションのみを対象とし、ショートや同リスト外の証券は含みません。
  • 最新四半期をまだ提出していない運用者はゼロではなく不在です。提出期限は四半期末から最長45日です。
  • 差は2つの四半期末時点の差であり、取引ではありません。
  • 別の運用者の名義で報告された保有は、その運用者の提出書類にも現れることがあるため、行を合算しないでください。
  • 証券リストがこの会社に結び付けられない、または曖昧にしか結び付けられない保有は表示しません。

5%保有者(Schedule 13D・13G)

SECの構造化形式(2024年末以降)で提出されたスケジュールをここで読み取ります。それ以前のものは自由形式のテキストで、読み取っていません。

5%保有者(新しい事由順、提出どおり)
保有者クラスに占める割合保有株数事由日書式出典
AH Bio Fund II, L.P. Common Stock, $0.001 par value per share12.62,385,075.0009/30/2026 2026年11月16日に提出SCHEDULE 13G提出書類を開く 0001725721-26-000009 この行に異議を申し立てる
AH Equity Partners Bio II, L.L.C. Common Stock, $0.001 par value per share12.62,385,075.0009/30/2026 2026年11月16日に提出SCHEDULE 13G提出書類を開く 0001725721-26-000009 この行に異議を申し立てる
AH Bio Fund III, L.P. Common Stock, $0.001 par value per share3.7697,650.0009/30/2026 2026年11月16日に提出SCHEDULE 13G提出書類を開く 0001725721-26-000009 この行に異議を申し立てる
AH Equity Partners Bio III, L.L.C. Common Stock, $0.001 par value per share3.7697,650.0009/30/2026 2026年11月16日に提出SCHEDULE 13G提出書類を開く 0001725721-26-000009 この行に異議を申し立てる
Marc L. Andreessen Common Stock, $0.001 par value per share16.33,082,725.0009/30/2026 2026年11月16日に提出SCHEDULE 13G提出書類を開く 0001725721-26-000009 この行に異議を申し立てる
Benjamin A. Horowitz Common Stock, $0.001 par value per share16.33,082,725.0009/30/2026 2026年11月16日に提出SCHEDULE 13G提出書類を開く 0001725721-26-000009 この行に異議を申し立てる
RA Capital Management, L.P. Common Stock, $0.001 par value per share9.61,802,178.0007/27/2026 2026年8月3日に提出SCHEDULE 13G提出書類を開く 0001346824-26-000210 この行に異議を申し立てる
Peter Kolchinsky Common Stock, $0.001 par value per share9.61,802,178.0007/27/2026 2026年8月3日に提出SCHEDULE 13G提出書類を開く 0001346824-26-000210 この行に異議を申し立てる
Rajeev Shah Common Stock, $0.001 par value per share9.61,802,178.0007/27/2026 2026年8月3日に提出SCHEDULE 13G提出書類を開く 0001346824-26-000210 この行に異議を申し立てる
RA Capital Healthcare Fund, L.P. Common Stock, $0.001 par value per share9.11,714,582.0007/27/2026 2026年8月3日に提出SCHEDULE 13G提出書類を開く 0001346824-26-000210 この行に異議を申し立てる
ORBIMED ADVISORS LLC Common Stock7.21,348,825.0007/27/2026 2026年7月29日に提出SCHEDULE 13D提出書類を開く 0000947871-26-000732 この行に異議を申し立てる
ORBIMED CAPITAL GP VIII LLC Common Stock7.21,348,825.0007/27/2026 2026年7月29日に提出SCHEDULE 13D提出書類を開く 0000947871-26-000732 この行に異議を申し立てる
Avoro Capital Advisors LLC Common Stock, $0.001 par value per share13.782,598,973.0007/24/2026 2026年7月30日に提出SCHEDULE 13D提出書類を開く 0000902664-26-003281 この行に異議を申し立てる
Avoro Ventures LLC Common Stock, $0.001 par value per share2.60489,915.0007/24/2026 2026年7月30日に提出SCHEDULE 13D提出書類を開く 0000902664-26-003281 この行に異議を申し立てる
Aghazadeh Behzad Common Stock, $0.001 par value per share16.373,088,888.0007/24/2026 2026年7月30日に提出SCHEDULE 13D提出書類を開く 0000902664-26-003281 この行に異議を申し立てる
ELI LILLY Co Common stock, $0.001 par value per share7.31,388,161.0007/23/2026 2026年7月30日に提出SCHEDULE 13D提出書類を開く 0000059478-26-000072 この行に異議を申し立てる

割合は提出書類が指定するクラスに対するもので、保有者の申告どおりです。グループの構成員はそれぞれグループの株式を報告するため、行を合算しないでください。

読み込んだ内容

2004年6月14日から2026年11月17日までの提出書類2,241,208件を読み込み:Form 3, 3/A, 4, 4/A, 5, 5/A。

アーカイブの読み込み中は、不完全な年があります。ここで提出数が少ない年が、実際に少なかったという意味ではありません。

提出年別の読み込み件数
提出年読み込み件数
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
2022158,941
2023199,811
2024209,823
2025235,520
2026260,174

SECがXMLを義務付ける前の提出書類は一覧にあるだけで、内容は抽出していません。

Scribe Therapeutics, Inc.に戻る